Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kezar Life Sciences, Inc. (KZR : NSDQ)

• Company Description    Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. Number of Employees: 56

• Price / Volume Information    Yesterday's Closing Price: $5.54 Daily Weekly Monthly 20 Day Moving Average: 1,635,891 shares Shares Outstanding: 60.42 (millions) Market Capitalization: $334.70 (millions) Beta: 0.50 52 Week High: $18.55 52 Week Low: $4.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -59.26% -55.40% 12 Week -61.55% -56.79% Year To Date -66.87% -59.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4000 SHORELINE COURT SUITE 300 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-822-5600 fax: - ir@kezarbio.com http://www.kezarlifesciences.com

• General Corporate Information    Officers John Fowler - Chief Executive Officer and Director Jean-Pierre Sommadossi - Chairman Marc Belsky - Chief Financial Officer and Secretary Franklin Berger - Director Graham Cooper - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 49372L100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 60.42 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $334.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -4.00% vs. Previous Quarter: -4.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -33.99 12/31/21 - -37.23 09/30/21 - -38.69 ROA 03/31/22 - -31.15 12/31/21 - -34.10 09/30/21 - -35.74 Current Ratio 03/31/22 - 35.25 12/31/21 - 25.77 09/30/21 - 15.85 Quick Ratio 03/31/22 - 35.25 12/31/21 - 25.77 09/30/21 - 15.85 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 4.10 12/31/21 - 4.01 09/30/21 - 2.48 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.04 12/31/21 - 0.05 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 4.00 12/31/21 - 4.66 09/30/21 - 0.00

Powered by Zacks Investment Research ©